Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To access the efficacy and safety of Meloxicam 7.5 mg and 15 mg once daily compared with
Mefenamic acid 500 mg t.i.d. over a treatment period of 3-5 days, during an observation
period of 3 menstrual cycles, for the symptomatic relief of primary dysmenorrhea